| Open |
S2427 |
BRIGHT |
9/4/2025 |
|
30% |
|
|
| Open |
S2409 |
PRISM |
9/8/2025 |
|
2% |
|
|
| Open |
21CTP.HN01 |
CAPT-HN Phase II Study of Amivantamab carboPlatin and pacliTaxel in recurrent metastatic Head and Neck cancer (CAPT-HN) Study Synopsis |
9/15/2025 |
|
16% |
|
|
| Open |
S2433 |
Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma |
12/26/2025 |
|
1% |
|
|
| Open |
SN2426 |
Phase II Study of Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma |
1/28/2026 |
|
9% |
|
|
| Open |
S2419 |
BioFront |
4/22/2026 |
|
2% |
|
|
| Open |
S2504 |
A Randomized Phase III Study of Pirtobrutinib plus R-CHOP vs. R-CHOP for Patients with Previously Unt |
6/1/2026 |
|
1% |
|
|
| Open |
S2424CD |
Testing an educational program to improve goals of care conversations between patients and their care teams |
6/1/2026 |
|
0% |
|
|
| Open |
S1900N |
Treatment for Advanced Non-Small Cell Lung Cancer with Actionable Genomic Alterations after Targeted Treatment and Chemotherapy (Lung-MAP Sub-study) |
8/3/2026 |
|
0% |
|
|
